Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA; MDS Clinical Research Consortium. Nazha A, et al. Among authors: list af. Haematologica. 2016 Jun;101(6):e224-7. doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18. Haematologica. 2016. PMID: 26992944 Free PMC article. Clinical Trial. No abstract available.
Myelodysplastic syndromes.
List AF, Vardiman J, Issa JP, DeWitte TM. List AF, et al. Hematology Am Soc Hematol Educ Program. 2004:297-317. doi: 10.1182/asheducation-2004.1.297. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561689 Review.
Developmental therapeutics for myelodysplastic syndromes.
Naing A, Sokol L, List AF. Naing A, et al. Among authors: list af. J Natl Compr Canc Netw. 2006 Jan;4(1):78-82. doi: 10.6004/jnccn.2006.0008. J Natl Compr Canc Netw. 2006. PMID: 16403406 Review.
Immunomodulation in myelodysplastic syndromes.
Sekeres MA, List A. Sekeres MA, et al. Best Pract Res Clin Haematol. 2006;19(4):757-67. doi: 10.1016/j.beha.2006.06.001. Best Pract Res Clin Haematol. 2006. PMID: 16997181 Review.
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, Feldman EJ, Roboz GJ. Giles FJ, et al. Among authors: list af. Leuk Res. 2007 Jul;31(7):891-7. doi: 10.1016/j.leukres.2006.12.001. Leuk Res. 2007. PMID: 17560285 Clinical Trial.
Lenalidomide in myelodysplastic syndromes.
List AF. List AF. Clin Adv Hematol Oncol. 2008 Apr;6(4):271-2, 311. Clin Adv Hematol Oncol. 2008. PMID: 18496493 No abstract available.
325 results